Kevin B. Bacon
Directeur Général chez Abcentra, Inc.
Profil
Kevin B.
Bacon was the founder of Actimis Pharmaceuticals, Inc. (founded in 2004) and Axikin Pharmaceuticals, Inc. (founded in 2008), where he held the titles of Chief Scientific Officer and President, Director & Chief Scientific Officer, respectively.
Currently, he is the Chief Executive Officer at Abcentra, Inc. (since 2020) and the President, Chief Executive Officer & Director at Sequoia Vaccines, Inc. (since 2023).
Previously, he was the Chief Executive Officer at Raft Pharmaceuticals LLC (2018-2020), Associate Director at Neurocrine Biosciences, Inc., Principal at Bayer AG (1999-2004), Vice President-Respiratory Diseases Research at Bayer HealthCare AG (1999-2004), and Principal at DNAX Research, Inc. He holds a doctorate from the University of London and an undergraduate degree from King's College London.
Postes actifs de Kevin B. Bacon
| Sociétés | Poste | Début |
|---|---|---|
Abcentra, Inc.
 Abcentra, Inc. Miscellaneous Commercial ServicesCommercial Services Abcentra, Inc. is an American clinical-stage biopharmaceutical company that specializes in developing novel antibody therapies for inflammatory diseases, with a particular focus on cardiovascular disease. The private company's patented technology allows for the targeting of oxidized lipoproteins and associated inflammatory responses. Abcentra's pipeline focuses on patient populations with high-risk of cardiometabolic complications that are exacerbated by chronic inflammation, including patients with inflammatory diseases and patients with residual inflammation. The company's lead compound, orticumab, is a novel monoclonal antibody that blocks inflammation from oxidized low-density lipoprotein and is slated to begin a phase 2 study later this year. Kevin B. Bacon has been the CEO of the company since 2020. | Directeur Général | 15/06/2020 |
Sequoia Vaccines, Inc.
 Sequoia Vaccines, Inc. BiotechnologyHealth Technology Sequoia Vaccines, Inc. is a clinical stage pharmaceutical company engages in developing vaccine to prevent recurrent urinary tract infections and small molecules treating cancers and bacterial infections. The company was founded by Gary Eldridge in 2012 and is headquartered in St. Louis, MO. | Directeur Général | 01/04/2023 |
Anciens postes connus de Kevin B. Bacon
| Sociétés | Poste | Fin |
|---|---|---|
| Raft Pharmaceuticals LLC | Directeur Général | 01/01/2020 |
Actimis Pharmaceuticals, Inc.
 Actimis Pharmaceuticals, Inc. BiotechnologyHealth Technology Actimis Pharmaceuticals, Inc. provides pharmaceutical research and development services. it focuses on the development of small therapeutics for respiratory and inflammatory disorders. The company was founded by Kevin B. Bacon in November 2004 and is headquartered in San Diego, CA. | Fondateur | 01/02/2018 |
Axikin Pharmaceuticals, Inc.
 Axikin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axikin Pharmaceuticals Inc. operates as a biopharmaceutical company. It develops and commercializes small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis. The company was founded by Kevin Bacon in June 2008 and is headquartered in San Diego, CA. | Fondateur | 01/01/2017 |
| BAYER AG | Corporate Officer/Principal | 01/01/2004 |
Bayer HealthCare AG
 Bayer HealthCare AG Pharmaceuticals: MajorHealth Technology Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany. | Corporate Officer/Principal | 01/01/2004 |
Formation de Kevin B. Bacon
| University of London | Doctorate Degree |
| King's College London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BAYER AG | Health Technology |
| NEUROCRINE BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Actimis Pharmaceuticals, Inc.
Actimis Pharmaceuticals, Inc. BiotechnologyHealth Technology Actimis Pharmaceuticals, Inc. provides pharmaceutical research and development services. it focuses on the development of small therapeutics for respiratory and inflammatory disorders. The company was founded by Kevin B. Bacon in November 2004 and is headquartered in San Diego, CA. | Health Technology |
Axikin Pharmaceuticals, Inc.
Axikin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axikin Pharmaceuticals Inc. operates as a biopharmaceutical company. It develops and commercializes small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis. The company was founded by Kevin Bacon in June 2008 and is headquartered in San Diego, CA. | Health Technology |
| DNAX Research, Inc. | |
Abcentra, Inc.
Abcentra, Inc. Miscellaneous Commercial ServicesCommercial Services Abcentra, Inc. is an American clinical-stage biopharmaceutical company that specializes in developing novel antibody therapies for inflammatory diseases, with a particular focus on cardiovascular disease. The private company's patented technology allows for the targeting of oxidized lipoproteins and associated inflammatory responses. Abcentra's pipeline focuses on patient populations with high-risk of cardiometabolic complications that are exacerbated by chronic inflammation, including patients with inflammatory diseases and patients with residual inflammation. The company's lead compound, orticumab, is a novel monoclonal antibody that blocks inflammation from oxidized low-density lipoprotein and is slated to begin a phase 2 study later this year. Kevin B. Bacon has been the CEO of the company since 2020. | Commercial Services |
| Raft Pharmaceuticals LLC | |
Sequoia Vaccines, Inc.
Sequoia Vaccines, Inc. BiotechnologyHealth Technology Sequoia Vaccines, Inc. is a clinical stage pharmaceutical company engages in developing vaccine to prevent recurrent urinary tract infections and small molecules treating cancers and bacterial infections. The company was founded by Gary Eldridge in 2012 and is headquartered in St. Louis, MO. | Health Technology |
Bayer HealthCare AG
Bayer HealthCare AG Pharmaceuticals: MajorHealth Technology Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany. | Health Technology |